comparemela.com

Latest Breaking News On - Regulatory services provider - Page 8 : comparemela.com

Satellos Bioscience Inc : Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights

Toronto, Ontario (Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle

Canadian Net REIT Announces its Results for the Quarter Ended September 30, 2022, an Increase in its Per Unit Distributions for 2023 and Q1 2023 Monthly Distributions

Canadian Net REIT Announces its Results for the Quarter Ended September 30, 2022, an Increase in its Per Unit Distributions for 2023 and Q1 2023 Monthly Distributions
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Satellos Bioscience Inc : Satellos Bioscience Announces Advancement of Compounds to Next Stage of Development

-Proof of concept studies to be completed by YE- Toronto, Ontario (Newsfile Corp. - November 3, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company developing

Satellos Bioscience Inc : Satellos Bioscience Announces OTCQB Listing in the United States

Toronto, Ontario (Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Corporation"), a drug discovery company aimed at developing therapeutics

Satellos Bioscience Inc Announces Licensing of Formulation Technology and Expanded Collaboration with NW PharmaTech Ltd

Satellos Bioscience Inc Announces Licensing of Formulation Technology and Expanded Collaboration with NW PharmaTech Ltd
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.